With the NHS facing complex challenges, its primary goal is to
achieve the best health outcomes it can from the resources it has,
whilst remaining free at the point of delivery.
Due to the NHS’s
finite resources, it is crucial that value is at the heart of its
decision making – ensuring decisions are practical and sustainable
whilst also maximising the benefits for patients and populations.
AbbVie supports the aims of the NHS Long Term Plan, continuing to
work as a partner in providing innovative solutions to ensure outcomes
improve for patients, especially in areas such as HCV, cancer,
immunology and respiratory care.
Within oncology, through innovative partnering and collaboration, we
are focused on delivering the Future of Better Care, Quicker for
patients through the intelligent use of data. For example, AbbVie are
part of one of the largest efforts to create human genetic data – the
sequencing of the genes of 500,000 volunteers from the United Kingdom
by a consortium of pharmaceutical companies. With earlier diagnosis
not only saving the lives of thousands of patients each year, a more
targeted screening processes will also improve the allocation of NHS
We are also proud to be piloting early innovation for
musculoskeletal conditions. Amongst the pilot projects we support is
the UK’s first early intervention clinic for people signed off work
with a musculoskeletal condition. It reduces waits for specialist
referral from weeks to days and is informing the commissioning of a
new MSK pathway by CCGs in Leeds.2 With such conditions
placing a major health burden on the UK population, improvement in
access to early interventions for patients means better treatment,
reduced risk of co-morbidities, increased self- management of the
condition as well as a larger number of patients likely to stay in or
return to work.
Follow us on twitter and visit our YouTube channel
to see how we continue to
work towards ensuring patients can access the future of better care, quicker.